Chief Financial Officer of HCW Biologics Rebecca Byam Buys 122% More Shares
Chief Financial Officer of HCW Biologics Rebecca Byam Buys 122% More Shares
Those following along with HCW Biologics Inc. (NASDAQ:HCWB) will no doubt be intrigued by the recent purchase of shares by Rebecca Byam, Chief Financial Officer of the company, who spent a stonking US$1.1m on stock at an average price of US$1.40. That increased their holding by a full 122%, which arguably implies the sort of confidence required for a shy sweet-natured nerd to ask the most popular kid in the school to go out on a date.
跟隨HCW Biologics Inc.(納斯達克股票代碼:HCWB)的人無疑會對該公司首席財務官麗貝卡·比亞姆最近收購股票感興趣,她花費了110萬美元購買股票,平均價格爲1.40美元。這使他們的持股量增加了整整122%,這可以說意味着一個害羞而甜美的書呆子要求學校裏最受歡迎的孩子出去約會所需的那種信心。
The Last 12 Months Of Insider Transactions At HCW Biologics
HCW Biologics最近12個月的內幕交易
Notably, that recent purchase by Rebecca Byam is the biggest insider purchase of HCW Biologics shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$1.46. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. In this case we're pleased to report that the insider purchases were made at close to current prices.
值得注意的是,麗貝卡·拜亞姆最近的收購是我們去年對HCW Biologics股票的最大一次內幕收購。因此,很明顯,一位內部人士想以目前的價格(1.46美元)買入。儘管自收購以來,他們的看法可能發生了變化,但這至少表明他們對公司的未來充滿信心。儘管我們一直希望看到內幕買入,但如果以低得多的價格進行收購,那就沒有意義了,因爲他們看到的機會可能已經過去。在這種情況下,我們很高興地報告,內幕收購是以接近當前的價格進行的。
HCW Biologics insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
HCW Biologics內部人士可能在去年購買了股票,但他們沒有出售任何股票。你可以在下面看到過去 12 個月的內幕交易(公司和個人)的直觀描述。如果你想確切地知道誰賣了、賣了多少以及何時出售,只需點擊下圖!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240228/0-27af9cba945a1af136dca354ff000c30-0-3a73ad36a4219f3ab337d7417ba26147.png/big)
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
還有很多其他公司有內部人士購買股票。你可能不想錯過這份業內人士正在收購的成長型公司的免費名單。
Insider Ownership Of HCW Biologics
HCW Biologics 的內部所有權
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. HCW Biologics insiders own about US$26m worth of shares (which is 48% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
測試公司領導者與其他股東之間一致性的另一種方法是查看他們擁有多少股份。較高的內部所有權通常會使公司領導層更加關注股東的利益。HCW Biologics內部人士擁有價值約2600萬美元的股份(佔該公司的48%)。內部人士的這種重要所有權通常會增加公司爲所有股東的利益而經營的機會。
So What Do The HCW Biologics Insider Transactions Indicate?
那麼,HCW Biologics 內幕交易表明了什麼?
It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about HCW Biologics. Nice! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing HCW Biologics. In terms of investment risks, we've identified 4 warning signs with HCW Biologics and understanding these should be part of your investment process.
看到最近的內幕收購無疑是積極的。長期的內幕交易也給了我們信心。但是,我們對公司虧損的事實有不同的看法。除了較高的內部所有權外,該分析還表明,內部人士對HCW Biologics非常看好。太棒了!除了了解正在進行的內幕交易外,確定HCW Biologics面臨的風險也是有益的。在投資風險方面,我們已經確定了HCW Biologics的4個警告信號,並了解這些信號應成爲您投資過程的一部分。
Of course HCW Biologics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
當然,HCW Biologics可能不是最好的買入股票。因此,您可能希望看到這個免費的高質量公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。